Growth hormone therapy after hematopoietic cell transplantation in childhood: a nationwide survey and longitudinal cohort study - Takeaways - MDSpire

Growth hormone therapy after hematopoietic cell transplantation in childhood: a nationwide survey and longitudinal cohort study

  • By

  • Maiko Shimomura

  • Hiroshi Kawaguchi

  • Eisuke Inoue

  • Reiko Kagawa

  • Satoshi Okada

  • Shohei Yamamoto

  • Maho Sato

  • Kana Washio

  • Miho Ashiarai

  • Shoji Saito

  • Akira Hayakawa

  • Yasuo Ejima

  • Hiroshi Fuji

  • Shuichi Ozono

  • Hirotoshi Sakaguchi

  • Katsuyoshi Koh

  • Koji Kato

  • Katsutsugu Umeda

  • May 20, 2026

  • 0 min

Share

  • 1

    Growth hormone therapy significantly improves height outcomes in childhood hematopoietic cell transplantation survivors with short stature.

  • 2

    Factors like total body irradiation and chronic graft-versus-host disease are linked to poorer height outcomes after transplantation.

  • 3

    GH responsiveness varies by transplant type, with absence of total body irradiation and female sex being favorable in allogeneic HCT.

  • 4

    GH therapy does not increase the risk of complications such as slipped capital femoral epiphysis or secondary malignancies.

  • 5

    Optimizing GH therapy and developing strategies for patients with poor expected responses are crucial for improving height outcomes.

Original Source(s)

Related Content